Rallybio

Rallybio P/B

The P/B (Price-to-Book Ratio) of Rallybio (RLYB) as of Oct 21, 2026 is 0.44. In the previous year, P/B (Price-to-Book Ratio) was 0.41 — a change of 6.38% (higher).

P/B

0.44

YoY

6.38%

Last updated:

P/B (Price-to-Book Ratio) of Rallybio is 2025 0.44 . P/B (Price-to-Book Ratio) of Rallybio was 2024 0.41 . It decreases by 6.38% higher compared to the previous year.

The Rallybio P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2019
1.51 USD
Jan 1, 2020
0.19 USD
Jan 1, 2021
0.14 USD
Jan 1, 2022
0.15 USD
Jan 1, 2023
0.24 USD
Jan 1, 2024
0.41 USD
Jan 1, 2025
0.44 USD
The Rallybio P/B history
YEARP/BYoY
0.44+6.38%
0.41+72.23%
0.24+59.46%
0.15+3.71%
0.14-22.55%
0.19-87.60%
1.51—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rallybio Stock analysis

What does Rallybio do? Rallybio Corp. generates revenue by identifying, researching, and developing clinical biotechnology products and therapies for severe and rare diseases. The firm focuses on accelerating the development of life-transforming therapies, with a specific program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare hematological disease affecting fetuses and newborns. The company's pipeline includes several candidates such as RLYB212, a subcutaneously administered human monoclonal anti-HPA-1a antibody candidate for preventing HPA-1a maternal alloimmunization and FNAIT occurrence. Additionally, the advanced product candidate RLYB116 serves as an inhibitor of complement component 5 (C5) to treat complement dysregulation conditions including paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). The pipeline also features RLYB114, a pegylated C5-targeted Affibody molecule, and the ENPP1 Program, alongside RLYB331, targeting patients with these specific medical needs. Rallybio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rallybio stock

P/B (Price-to-Book Ratio) of Rallybio is 0.44 in 2025.

P/B (Price-to-Book Ratio) of Rallybio changed from 0.41 to 0.44, representing a 6.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Rallybio since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Rallybio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Rallybio

All Key Metrics — Rallybio